![]() He is currently a member of the Board of Governors of CancerLinQ LLC, a wholly-owned non-profit subsidiary of the American Society of Clinical Oncology and a member of the Board of the Mission Hospital Foundation. Andrews had been serving as Chief Executive Officer. Andrews served as Chief Executive Officer of GE Molecular Diagnostics, a position he assumed upon GE’s acquisition of Clarient Inc., a NASDAQ-listed oncology-focused clinical laboratory service company, at which Mr. Andrews led the integration of Life Technologies’ next generation sequencing technology into the Thermo Fisher product line. Andrews most recently served as President of the Genetic Sciences Division of Thermo Fisher Scientific, a position he assumed upon Thermo Fisher’s acquisition of Life Technologies Corporation, where he had been the President of the Medical Sciences Venture. Their experience and insights will provide valuable guidance as we continue to grow our business and expand our product offerings.” “Ronnie brings more than 30 years of clinical and molecular diagnostics industry experience, and Scott brings substantial experience building and growing lab services businesses. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We are pleased to expand our Board of Directors through the addition of Ronnie and Scott," said Dr. ![]() Walton to Oxford Immunotec’s Board of Directors increases the total number of directors to eight. Scott Walton will join the Company’s Board of Directors effective November 4, 2015. 03, 2015 (GLOBE NEWSWIRE) - Oxford Immunotec Global PLC (NASDAQ:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that experienced diagnostics executives Ronald Andrews Jr. Processing over a million specimens each year allows us to provide real-time analytics regarding emerging drug use trends, such as our studies published in JAMA and our most recent Millennium Health Signals Report ™.OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. Clinical drug testing is used in various healthcare settings to obtain objective information about patients' recent use of prescription medications and illicit drugs. Walton earned his bachelor's degree from Yale University and a Master of Business Administration degree from the Harvard Business School.Ībout Millennium Health Millennium Health is an accredited specialty laboratory with over a decade of experience delivering timely, accurate, clinically-actionable information through our nationwide medication monitoring and drug testing services. Before leading the esoteric businesses at LabCorp, Walton had numerous roles within the company including heading up strategic planning and mergers and acquisitions and served as the company's Chief Information Officer. Prior to that, he held a number of senior leadership positions at LabCorp, most recently as Executive Vice President of the esoteric testing business and as a member of LabCorp's five-person Executive Committee. Walton was previously CEO at Ameritox and Inform Diagnostics and served as a board member at Oxford Immunotec. I am committed to continuing to support our extraordinarily important mission, as well as the market leading lab testing, customer service, reporting, thought leadership, and compliance that the industry has come to expect from Millennium Health." "I feel very fortunate to be joining Millennium Health at such an exciting time in the Company's history. ![]() "Medication monitoring and drug testing are critical in helping address some of society's most pressing health care and public health challenges" said Walton. "With over twenty years of experience working in both public and private clinical diagnostics companies, Scott's expertise in strategic planning, mergers and acquisitions, information technology, and operations will be a great addition to the leadership team already in place at the Company." "We are very excited to have an executive with such deep industry experience as Scott joining Millennium Health as our new CEO," said Andrew Milgram, Chairman of the Board. 26, 2021 /PRNewswire/ - Millennium Health, a national leader in specialty medication monitoring and drug testing, today announced the appointment of Scott Walton as Chief Executive Officer (CEO) effective immediately.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |